The global technetium-99m market size is calculated at USD 7.49 billion in 2025 and is forecasted to reach around USD 11.46 billion by 2034, accelerating at a CAGR of 4.83% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Technetium-99m Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Technetium-99m Market, by Clinical Service
8.1.1 Bone Scans
8.1.1.1. Market Revenue and Forecast
8.1.2. Renal Scans
8.1.2.1. Market Revenue and Forecast
8.1.3. Cardiac Scans
8.1.3.1. Market Revenue and Forecast
8.1.4. Neurology Scans
8.1.4.1. Market Revenue and Forecast
9.1. Technetium-99m Market, by Isotopic Application
9.1.1. Gamma Camera
9.1.1.1. Market Revenue and Forecast
9.1.2. Single Photon Emission Computed Tomography
9.1.2.1. Market Revenue and Forecast
10.1. Technetium-99m Market, by End-User
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Diagnostic Centers
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Clinical Service
11.1.2. Market Revenue and Forecast, by Isotopic Application
11.1.3. Market Revenue and Forecast, by End-User
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Clinical Service
11.1.4.2. Market Revenue and Forecast, by Isotopic Application
11.1.4.3. Market Revenue and Forecast, by End-User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Clinical Service
11.1.5.2. Market Revenue and Forecast, by Isotopic Application
11.1.5.3. Market Revenue and Forecast, by End-User
11.2. Europe
11.2.1. Market Revenue and Forecast, by Clinical Service
11.2.2. Market Revenue and Forecast, by Isotopic Application
11.2.3. Market Revenue and Forecast, by End-User
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Clinical Service
11.2.4.2. Market Revenue and Forecast, by Isotopic Application
11.2.4.3. Market Revenue and Forecast, by End-User
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Clinical Service
11.2.5.2. Market Revenue and Forecast, by Isotopic Application
11.2.5.3. Market Revenue and Forecast, by End-User
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Clinical Service
11.2.6.2. Market Revenue and Forecast, by Isotopic Application
11.2.6.3. Market Revenue and Forecast, by End-User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Clinical Service
11.2.7.2. Market Revenue and Forecast, by Isotopic Application
11.2.7.3. Market Revenue and Forecast, by End-User
11.3. APAC
11.3.1. Market Revenue and Forecast, by Clinical Service
11.3.2. Market Revenue and Forecast, by Isotopic Application
11.3.3. Market Revenue and Forecast, by End-User
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Clinical Service
11.3.4.2. Market Revenue and Forecast, by Isotopic Application
11.3.4.3. Market Revenue and Forecast, by End-User
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Clinical Service
11.3.5.2. Market Revenue and Forecast, by Isotopic Application
11.3.5.3. Market Revenue and Forecast, by End-User
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Clinical Service
11.3.6.2. Market Revenue and Forecast, by Isotopic Application
11.3.6.3. Market Revenue and Forecast, by End-User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Clinical Service
11.3.7.2. Market Revenue and Forecast, by Isotopic Application
11.3.7.3. Market Revenue and Forecast, by End-User
11.4. MEA
11.4.1. Market Revenue and Forecast, by Clinical Service
11.4.2. Market Revenue and Forecast, by Isotopic Application
11.4.3. Market Revenue and Forecast, by End-User
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Clinical Service
11.4.4.2. Market Revenue and Forecast, by Isotopic Application
11.4.4.3. Market Revenue and Forecast, by End-User
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Clinical Service
11.4.5.2. Market Revenue and Forecast, by Isotopic Application
11.4.5.3. Market Revenue and Forecast, by End-User
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Clinical Service
11.4.6.2. Market Revenue and Forecast, by Isotopic Application
11.4.6.3. Market Revenue and Forecast, by End-User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Clinical Service
11.4.7.2. Market Revenue and Forecast, by Isotopic Application
11.4.7.3. Market Revenue and Forecast, by End-User
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Clinical Service
11.5.2. Market Revenue and Forecast, by Isotopic Application
11.5.3. Market Revenue and Forecast, by End-User
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Clinical Service
11.5.4.2. Market Revenue and Forecast, by Isotopic Application
11.5.4.3. Market Revenue and Forecast, by End-User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Clinical Service
11.5.5.2. Market Revenue and Forecast, by Isotopic Application
11.5.5.3. Market Revenue and Forecast, by End-User
12.1. Advanced Accelerator Applications S.A.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Advanced Cyclotron Systems, Inc
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bayer AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GE Healthcare
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Philips Healthcare
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Siemens Healthineers
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Eckert & Ziegler
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. IBA Radio Pharma Kft
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Medi Radio Pharma
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Lantheus Holdings Inc
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description